 |
市場調查報告書
商品編碼
1672642
血漿衍生藥物市場（按產品、應用、分銷管道和地區分類）Plasma Derived Medicine Market, By Product, By Application, By Distribution Channel, By Geography |
||||||
2025 年全球血漿藥物市場規模估計為 198.7 億美元，預計到 2032 年將達到 327.7 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.4%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 198.7億美元 |
| 效能資料 | 從 2020 年到 2024 年 | 預測期 | 2025 至 2032 年 |
| 預測期：2025-2032年複合年成長率： | 7.40％ | 2032 年價值預測 | 327.7億美元 |
血漿藥物是利用人體血漿作為原料製成的。這些藥物用於治療多種罕見疾病，包括免疫不全症、出血性疾病和神經系統疾病。全球範圍內罕見疾病發病率的不斷上升以及治療方案的進步可能會推動對血漿療法的需求。此外，政府和私營部門加大對基於血漿衍生物的創新治療方法開發的投資可能會推動市場成長。然而，血漿衍生藥物的高成本和嚴格的法律規範可能會阻礙市場的成長。對實證醫學的日益重視和對新興市場的日益關注，很可能在不久的將來為血漿藥物提供者創造商機。
市場動態：
全球血漿衍生藥物市場的成長是由世界範圍內罕見免疫和出血性疾病的日益流行所推動的。擴大採用血漿療法治療免疫性血小板減少性疾病、低丙種球蛋白血症和神經系統疾病等疾病，正在推動市場成長。醫療保健支出的增加和支持血漿衍生物製造的不斷發展的監管指南也將推動市場成長。市場參與企業開發創新的分餾技術和專門的生物加工平台將促進血漿衍生藥物的生產。然而，血漿採集的高成本和複雜的製造過程可能會阻礙血漿衍生療法的快速商業化。有關安全性和功效評估的嚴格規定可能會給參與企業帶來挑戰。在亞洲和拉丁美洲的新興國家，由於替代療法有限，需求正在成長，這可能在不久的將來為製造商創造新的商機。
本研究的主要特點
本報告對全球血漿衍生藥物市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。
它揭示了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球血漿衍生藥物市場的主要企業簡介是根據公司亮點、產品系列、關鍵亮點、業績和策略等參數進行的。
主要企業包括工業公司、CSL 有限公司、Grifols SA、Octapharma AG、Kedrion SpA 等。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球血漿衍生藥物市場報告迎合了該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過分析全球血漿衍生藥物市場所使用的各種策略矩陣來促進他們的決策。
目錄
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管情景
- 產品發布/核准
- PEST分析
- PORTER 分析
- 併購情景
4. 2020 年至 2032 年全球血漿衍生藥物市場（按產品分類）（十億美元）
- 免疫球蛋白
- 凝血因子
- 白蛋白
- 其他
5. 2020 年至 2032 年全球血漿衍生藥物市場（按應用分類）（十億美元）
- 骨盆腔發炎 (PID)
- 出血性疾病
- Alpha-1 抗胰蛋白酶缺乏症 (AATD)
- 遺傳性血管性水腫（HAE）
- 慢性脫髓鞘多發性神經炎
- 格林-巴利綜合症
- 多灶性運動神經病變
- 肝臟疾病
- 原發性免疫性血小板減少性疾病
- 感染疾病
- 其他罕見疾病
6. 2020-2032 年全球血漿衍生藥物市場按分銷管道分類（十億美元）
- 醫院藥房
- 零售藥局
- 網路藥局
7. 2020 年至 2032 年全球血漿衍生藥物市場（按地區分類）（十億美元）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第8章 競爭格局
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, SA
- Octapharma AG
- Kedrion Biopharma
- LFB SA
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL（Bio Products Laboratory）
- Fresenius Kabi AG
- Kamada Pharmaceuticals
第 9 章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第10章參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Global Plasma Derived Medicine Market is estimated to be valued at USD 19.87 Bn in 2025 and is expected to reach USD 32.77 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 19.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.40% | 2032 Value Projection: | USD 32.77 Bn |
Plasma derived medicines are manufactured using human blood plasma as the raw material. These medicines are used for treating various rare diseases like immune deficiency disorders, bleeding disorders, neurological disorders and more. Growing prevalence of rare diseases across the globe and advancements in therapy options can boost demand for plasma derived therapies. Furthermore, rising investments by government and private sectors in developing innovative treatments based on plasma derivatives can drive the market growth. However, high costs associated with plasma derived medication and stringent regulatory frameworks can hamper the market growth. Increasing emphasis on evidence-based treatment and emerging markets in developing nations can offer opportunities for plasma derived medicine providers in the near future.
Market Dynamics:
Global plasma derived medicine market growth is driven by rising prevalence of rare immunological and bleeding disorders worldwide. Growing adoption of plasma therapies to treat conditions like immune thrombocytopenia, hypogammaglobulinemia and neurological disorders can drive the market growth. Increasing healthcare spending coupled with evolving regulatory guidelines supporting manufacture of plasma derivatives can also drive the market growth. Emergence of innovative fractionation techniques and development of specialized bioprocessing infrastructure by market players facilitates the production of plasma derived drugs. However, high costs involved in plasma collection and complex production processes can hamper the rapid commercialization of plasma derived therapy. Stringent regulations regarding safety and efficacy evaluation can pose challenges for market players. Growing demand in emerging Asian and Latin American countries due to limited availability of alternative treatments can offer novel opportunities for manufacturers in the near future.
Key features of the study:
This report provides in-depth analysis of the global plasma derived medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma derived medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Takeda Pharmaceutical Company Ltd., CSL Ltd., Grifols S.A., Octapharma AG, and Kedrion S.p.A
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market
Detailed Segmentation-
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Immunoglobulin
- Coagulation factors
- Albumin
- Others
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Pelvic Inflammatory Disease (PID)
- Bleeding Disorders
- Alpha-1 Antitrypsin Deficiency (AATD)
- Hereditary Angioedema (HAE)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Guillain-Barre Syndrome
- Multifocal Motor Neuropathy
- Liver Diseases
- Primary Immune Thrombocytopenia
- Infections
- Other Orphan Diseases
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma
- LFB S.A.
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Plasma Derived Medicine Market, By Product
- Global Plasma Derived Medicine Market, By Application
- Global Plasma Derived Medicine Market, By Distribution Channel
- Global Plasma Derived Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Plasma Derived Medicine Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Coagulation factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albumin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Plasma Derived Medicine Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Pelvic Inflammatory Disease (PID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bleeding Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Antitrypsin Deficiency (AATD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema (HAE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Guillain-Barre Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Multifocal Motor Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Immune Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Orphan Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Plasma Derived Medicine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Plasma Derived Medicine Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grifols, S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kedrion Biopharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LFB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
